This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, K. S. Articles by Henry, R. R. Search for Related Content PubMed PubMed Citation Articles by Park, K. S. Articles by Henry, R. R.

Troglitazone Regulation of Glucose Metabolism in Human Skeletal Muscle Cultures from Obese Type II Diabetic Subjects¹

Department of Medicine, University of California-San Diego, La Jolla, California 92093; and Veterans Affairs Medical Center, San Diego, California 92161

Address all correspondence and requests for reprints to: Robert R. Henry, M.D., Veterans Affairs Medical Center, San Diego (V111G), 3350 La Jolla Village Drive, San Diego, California 92161.

To determine the effects of troglitazone on abnormal skeletal muscle glucose metabolism, muscle cultures from type II diabetic patients were grown for 4–6 weeks and then fused for 4 days either without or with troglitazone (1–5 µg/mL; chronic studies) or had troglitazone added for 90 min (1–5 µg/mL) at completion of fusion (acute studies). Acute troglitazone treatment stimulated glucose uptake, but not glycogen synthase (GS) activity 2-fold (P < 0.05) in a dose-dependent fashion and to the same extent as the addition of maximal (33 nmol/L) insulin. Maximal chronic troglitazone (5 µg/mL for 4 days) increased both glucose uptake (from 9.0 ± 1.5 to 40.9 ± 8.1 pmol/mg protein·min; P < 0.05) and GS fractional velocity (from 5.4 ± 0.7% to 20.6 ± 6.3%; P < 0.05) by approximately 4-fold. At each concentration of chronic troglitazone, glucose uptake rates were similar in the absence and presence of maximal (33 nmol/L) insulin concentrations. In contrast, insulin-stimulated GS activity was greater (P < 0.05) when maximal chronic troglitazone and acute insulin were combined than when chronic troglitazone alone was used. After 4 days of troglitazone, GLUT1 messenger ribonucleic acid and protein increased about 2-fold (P < 0.05) without a change in GLUT4 or GS messenger ribonucleic acid and protein. We conclude that troglitazone has both acute and chronic effects to improve skeletal muscle glucose metabolism of obese type II diabetic subjects. These effects involve direct insulin mimetic stimulatory actions as well as indirect insulin-sensitizing properties.

This article has been cited by other articles:

				B.-S. Cha, T. P. Ciaraldi, K.-S. Park, L. Carter, S. R. Mudaliar, and R. R. Henry Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPAR{gamma} agonists Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E151 - E159. [Abstract] [Full Text] [PDF]

				K. Levin, O. Hother-Nielsen, J. E. Henriksen, and H. Beck-Nielsen Effects of Troglitazone in Young First-Degree Relatives of Patients With Type 2 Diabetes Diabetes Care, January 1, 2004; 27(1): 148 - 154. [Abstract] [Full Text] [PDF]

				H. M. Wilmsen, T. P. Ciaraldi, L. Carter, N. Reehman, S. R. Mudaliar, and R. R. Henry Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E354 - E362. [Abstract] [Full Text] [PDF]

				C. Dello Russo, V. Gavrilyuk, G. Weinberg, A. Almeida, J. P. Bolanos, J. Palmer, D. Pelligrino, E. Galea, and D. L. Feinstein Peroxisome Proliferator-activated Receptor gamma Thiazolidinedione Agonists Increase Glucose Metabolism in Astrocytes J. Biol. Chem., February 14, 2003; 278(8): 5828 - 5836. [Abstract] [Full Text] [PDF]

				M. M. Meyer, K. Levin, T. Grimmsmann, N. Perwitz, A. Eirich, H. Beck-Nielsen, and H. H. Klein Troglitazone Treatment Increases Protein Kinase B Phosphorylation in Skeletal Muscle of Normoglycemic Subjects at Risk for the Development of Type 2 Diabetes Diabetes, September 1, 2002; 51(9): 2691 - 2697. [Abstract] [Full Text] [PDF]

				B. M. Jucker, T. R. Schaeffer, R. E. Haimbach, T. S. McIntosh, D. Chun, M. Mayer, D. H. Ohlstein, H. M. Davis, S. A. Smith, A. R. Cobitz, et al. Normalization of Skeletal Muscle Glycogen Synthesis and Glycolysis in Rosiglitazone-Treated Zucker Fatty Rats: An In Vivo Nuclear Magnetic Resonance Study Diabetes, July 1, 2002; 51(7): 2066 - 2073. [Abstract] [Full Text] [PDF]

				Y.-B. Kim, T. P. Ciaraldi, A. Kong, D. Kim, N. Chu, P. Mohideen, S. Mudaliar, R. R. Henry, and B. B. Kahn Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110{beta} Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects Diabetes, February 1, 2002; 51(2): 443 - 448. [Abstract] [Full Text] [PDF]

				T. P. Ciaraldi, A. P.S. Kong, N. V. Chu, D. D. Kim, S. Baxi, M. Loviscach, R. Plodkowski, R. Reitz, M. Caulfield, S. Mudaliar, et al. Regulation of Glucose Transport and Insulin Signaling by Troglitazone or Metformin in Adipose Tissue of Type 2 Diabetic Subjects Diabetes, January 1, 2002; 51(1): 30 - 36. [Abstract] [Full Text] [PDF]

				F. Liu, J.-k. Kim, Y. Li, X.-q. Liu, J. Li, and X. Chen An Extract of Lagerstroemia speciosa L. Has Insulin-Like Glucose Uptake-Stimulatory and Adipocyte Differentiation-Inhibitory Activities in 3T3-L1 Cells J. Nutr., September 1, 2001; 131(9): 2242 - 2247. [Abstract] [Full Text] [PDF]

				I. Yokoyama, K. Yonekura, T. Moritan, M. Tateno, T. Momose, K. Ohtomo, Y. Inoue, and R. Nagai Troglitazone Improves Whole-Body Insulin Resistance and Skeletal Muscle Glucose Use in Type II Diabetic Patients J. Nucl. Med., July 1, 2001; 42(7): 1005 - 1010. [Abstract] [Full Text] [PDF]

				D. Konrad, R. Somwar, G. Sweeney, K. Yaworsky, M. Hayashi, T. Ramlal, and A. Klip The Antihyperglycemic Drug {alpha}-Lipoic Acid Stimulates Glucose Uptake via Both GLUT4 Translocation and GLUT4 Activation: Potential Role of p38 Mitogen-Activated Protein Kinase in GLUT4 Activation Diabetes, June 1, 2001; 50(6): 1464 - 1471. [Abstract] [Full Text]

				S. Yonemitsu, H. Nishimura, M. Shintani, R. Inoue, Y. Yamamoto, H. Masuzaki, Y. Ogawa, K. Hosoda, G. Inoue, T. Hayashi, et al. Troglitazone Induces GLUT4 Translocation in L6 Myotubes Diabetes, May 1, 2001; 50(5): 1093 - 1101. [Abstract] [Full Text]

				J. M. Way, W. W. Harrington, K. K. Brown, W. K. Gottschalk, S. S. Sundseth, T. A. Mansfield, R. K. Ramachandran, T. M. Willson, and S. A. Kliewer Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor {{gamma}} Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues Endocrinology, March 1, 2001; 142(3): 1269 - 1277. [Abstract] [Full Text] [PDF]

				I. Gabriely, R. Wozniak, M. Hawkins, and H. Shamoon Troglitazone Amplifies Counterregulatory Responses to Hypoglycemia in Nondiabetic Subjects J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 521 - 528. [Abstract] [Full Text]

				C. Fürnsinn, B. Brunmair, S. Neschen, M. Roden, and W. Waldhäusl Troglitazone Directly Inhibits CO2 Production from Glucose and Palmitate in Isolated Rat Skeletal Muscle J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 487 - 493. [Abstract] [Full Text]

				S. Schinner, C. Dellas, M. Schroder, C. A. Heinlein, C. Chang, J. Fischer, and W. Knepel Repression of Glucagon Gene Transcription by Peroxisome Proliferator-activated Receptor gamma through Inhibition of Pax6 Transcriptional Activity J. Biol. Chem., January 11, 2002; 277(3): 1941 - 1948. [Abstract] [Full Text] [PDF]